Likarda

Letrozole, the active ingredient in Likorda, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed in the treatment of postmenopausal hormone receptor‑positive breast cancer, including early‑stage and metastatic disease.

GNH USA supplies Likorda as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Letrozole is used in breast‑cancer management by reducing estrogen production, a key driver of hormone‑dependent tumors.

- Postmenopausal hormone receptor‑positive breast cancer: decreases recurrence risk and improves survival. - Adjuvant treatment of early‑stage breast cancer: lowers the chance of disease return after surgery. - Metastatic breast cancer: slows disease progression and extends overall survival.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Hot flashes - Joint and muscle pain - Fatigue - Nausea - Headache - Dizziness

Serious or Rare Side Effects: - Liver toxicity (elevated transaminases) - Severe bone loss leading to fractures - Pulmonary embolism - Myocardial infarction or other cardiovascular events - Anaphylactic or severe allergic reactions - QT interval prolongation on ECG

Patients should be monitored for specific safety concerns before and during therapy.

- Bone health monitoring: assess bone mineral density regularly. - Liver function assessment: check hepatic enzymes prior to initiation and periodically thereafter. - Cardiovascular evaluation: review history of thromboembolic disease or cardiac risk factors. - Pregnancy avoidance: contraindicated in pregnancy; ensure effective contraception. - Drug interaction review: evaluate concomitant medications that affect CYP2C19 or CYP3A4. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Letrozole may interact with other medicines that influence its metabolism or hormonal effects.

Major Interactions (Avoid): - Estrogen replacement therapy: may counteract letrozole’s aromatase inhibition. - Strong CYP2C19 inhibitors (e.g., fluconazole): can increase letrozole plasma levels. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise exposure and toxicity risk.

Moderate Interactions (Monitor Closely): - CYP2C19 inducers (e.g., rifampin): may reduce therapeutic effectiveness. - Warfarin: letrozole can alter INR, requiring closer coagulation monitoring. - Statins metabolized by CYP3A4: monitor for increased statin-related adverse effects.